Patients with ROS1 Rearrangement Positive Non-Small Cell Lung Cancer Benefit from Pemetrexed-Based Chemotherapy

被引：0
|
作者：
Song, Zhengbo [1 ]
Zhang, Yiping [2 ]
Yuz, Xinmin [1 ]
机构：
[1] Zhejiang Canc Hosp, Med Oncol, Hangzhou, Zhejiang, Peoples R China
[2] Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
Thymidylate synthetase; ros1; pemetrexed; efficacy;
D O I：
10.1016/j.jtho.2016.11.1659
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.02a-029
引用
收藏
页码：S1179 / S1180
页数：2
相关论文
共 50 条
  • [41] Zoledronic acid combined with chemotherapy in non-small cell lung cancer with bone metastasis
    Zhang, Jingnan
    Yu, Lisha
    Guan, Jing
    Zhang, Juan
    Pan, Yunfang
    Wang, Mei
    JOURNAL OF BUON, 2021, 26 (03): : 830 - 836
  • [42] Economic evaluation of toripalimab combined with chemotherapy in the treatment of non-small cell lung cancer
    Wang, Hao
    Long, Yunchun
    Xu, Yuan
    Liao, Li
    Zhou, Yujie
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [43] Risk factors of nephrotoxicity of maintenance pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung
    Kwok, Wang Chun
    Chiang, Ka Yan
    Ho, James Chung Man
    Lam, David Chi Leung
    Ip, Mary Sau Man
    Tam, Terence Chi Chun
    LUNG CANCER, 2021, 162 : 169 - 174
  • [44] Effectiveness of crizotinib in patients with ROS1-positive non-small-cell lung cancer: real-world evidence in Japan
    Nogami, Naoyuki
    Nakamura, Atsushi
    Shiraiwa, Naoko
    Kikkawa, Hironori
    Emir, Birol
    Wiltshire, Robin
    Morise, Masahiro
    FUTURE ONCOLOGY, 2023, 19 (37) : 2453 - 2463
  • [45] Immune Checkpoint Inhibitor Therapy for Patients With Non-small Cell Lung Cancer Ineligible for Platinum Doublet Chemotherapy
    Inomata, Minehiko
    Minatoyama, Shuhei
    Takata, Naoki
    Hayashi, Kana
    Hirai, Takahiro
    Seto, Zenta
    Tokui, Kotaro
    Taka, Chihiro
    Okazawa, Seisuke
    Kambara, Kenta
    Imanishi, Shingo
    Miwa, Toshiro
    Matsuyama, Kei
    Hayashi, Ryuji
    Matusi, Shoko
    Tobe, Kazuyuki
    ANTICANCER RESEARCH, 2024, 44 (03) : 1241 - 1245
  • [46] Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patients
    Morimoto, Kenji
    Yamada, Tadaaki
    Nakamura, Ryota
    Katayama, Yuki
    Tanaka, Satomi
    Takumi, Chieko
    Hiraoka, Noriya
    Ogura, Yuri
    Takeda, Takayuki
    Onoi, Keisuke
    Chihara, Yusuke
    Taniguchi, Ryusuke
    Yamada, Takahiro
    Matsui, Yohei
    Hiranuma, Osamu
    Morimoto, Yoshie
    Iwasaku, Masahiro
    Kaneko, Yoshiko
    Uchino, Junji
    Takayama, Koichi
    MEDICAL ONCOLOGY, 2020, 37 (12)
  • [47] Alvopem® (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance
    Seifi, Sharareh
    Salimi, Babak
    Monfared, Zahra Esfahani
    Sabahi, Cyrus
    Kafi, Hamidreza
    Khosravi, Adnan
    JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE, 2023, 16 (01)
  • [48] Bevacizumab Concomitant with Chemotherapy is Effective in Treating Chinese Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer
    Sun, Jing
    Hu, Yi
    Wu, Bai-Shou
    Wang, Jin-Liang
    Tao, Hai-Tao
    Zhang, Su-Jie
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (14) : 5945 - 5950
  • [49] A Nomogram to Predict the Overall Survival of Patients With Resected T1-2N0-1M0 Non-Small Cell Lung Cancer and to Identify the Optimal Candidates for Adjuvant Chemotherapy in Stage IB or IIA Non-Small Cell Lung Cancer Patients
    Wang, Wei
    Zhou, Juying
    CANCER CONTROL, 2023, 30
  • [50] Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment
    Jianya Zhou
    Jing Zheng
    Xiaochen Zhang
    Jing Zhao
    Yanping Zhu
    Qian Shen
    Yuehong Wang
    Ke Sun
    Zeying Zhang
    Zhijie Pan
    Yihong Shen
    Jianying Zhou
    BMC Cancer, 18
12345